We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Performance of Chagas Disease Genotyping Assay Evaluated

By LabMedica International staff writers
Posted on 07 Apr 2017
Print article
Image: Trypanosoma cruzi trypomastigote in a thin blood smear stained with Giemsa from a patient with Chagas disease (Photo courtesy of the CDC).
Image: Trypanosoma cruzi trypomastigote in a thin blood smear stained with Giemsa from a patient with Chagas disease (Photo courtesy of the CDC).
Chagas disease remains a significant public health issue infecting six to seven million people worldwide. The factors influencing the clinical heterogeneity of Chagas disease have not been elucidated, although it has been suggested that different clinical outcome may be associated with the genetic diversity of Trypanosoma cruzi isolates.

Differences in therapeutic response of distinct T. cruzi genotypes have been also reported. Typing strategies for genotype-specific diagnosis of Chagas disease to identify the T. cruzi discrete typing units (DTU) have already been developed, including biochemical and molecular methods, however the techniques have limitations.

Scientists at the Federal University of Ouro Preto used standard T. cruzi strains, representative of three major genotypes involved in the domestic cycle of Chagas disease in Brazil, to setup the TcI/TcVI/TcII Chagas-Flow ATE-IgG2a methodology for the serodiagnosis of T. cruzi infection. The team maintained the strains in mice and the infection was confirmed in all T. cruzi-infected mice, by positivity at fresh blood examination performed at day 7, 10 or 15 post-infection. The serum samples used for the TcI/TcVI/TcII Chagas-Flow ATE-IgG2a serology were prepared from whole blood samples collected by ocular plexus puncture.

The amastigote/trypomastigote/epimastigote forms of TcI, TcVI and TcII T. cruzi genotypes were obtained and the TcI/TcVI/TcII Chagas-Flow ATE-IgG2a serodiagnosis was performed. Flow cytometric data was acquired with a FACSCanto flow cytometer. Following the selection of target-antigens, one-dimensional histograms were employed to quantify the genotype-specific anti-T. cruzi IgG2a reactivity, based on the positivity limit set based on the internal control. The results were expressed as percentage of positive fluorescent parasites (PPFP) for each tested sample dilution.

The data acquired demonstrated that “α-TcII-TRYPO/1:500, cut-off/PPFP = 20%” presented an excellent performance for universal diagnosis of T. cruzi infection. The combined set of attributes “α-TcI-TRYPO/1:4,000, cut-off/PPFP = 50%”, “α-TcII-AMA/1:1,000, cut-off/PPFP = 40%” and “α-TcVI-EPI/1:1,000, cut-off/PPFP = 45%” showed good performance to segregate infections with TcI/Colombiana, TcVI/CL or TcII/Y strain. Overall, hosts infected with TcI/Colombiana and TcII/Y strains displayed opposite patterns of reactivity with “α-TcI TRYPO” and “α-TcII AMA”.

The authors concluded that the method presented a good performance for genotype-specific diagnosis, with global accuracy of 69% when the population/prototype scenario include TcI, TcVI and TcII infections and 94% when comprise only TcI and TcII infections. The method providing a feasible tool to classify serum samples from hosts infected with distinct T. cruzi genotypes, supporting the potential of this method for universal and genotype-specific diagnosis of T. cruzi infection. The study was published on March 23, 2017, in the journal Public Library of Science Neglected Tropical Diseases.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.